Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
pharmaphorum2d
Lilly on alert as new Kisqali approval threatens Verzenio
Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’
We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
ENDPOINTS NEWS2d
No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer
Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...